SavedAdd your journal

Journals / Balkan Medical Journal / 2012 / Cilt: 29 - Sayı: 2

The efficacy of botulinum toxin in patients with cervicogenic headache: A placebo-controlled clinical trial

Zeki ODABAŞI
Bilgin ÖZTÜRK
Yaşar KÜTÜKÇÜ
Ümit Hıdır ULAŞ
Ömer KARADAŞ
Pages
184–187
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: In the BoNTA group, the severity and frequency of pain 6 and 12 weeks post treatment were significantly lower than pre-treatment levels (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Botulinum toxin type-A (BoNTA) has been considered a treatment option for CH.
📊
Key Findings & Data:Patients in the BoNTA group (n=20) were administered 10 U of BoNTA bilaterally to the frontal muscles, 20 U to the temporal muscles, 15 U to the semispinalis capitis, 15 U to the splenius capitis, and 15 U to the trapezius muscles (total: 150 U).
💡
Conclusion & Impact:Results: In the BoNTA group, the severity and frequency of pain 6 and 12 weeks post treatment were significantly lower than pre-treatment levels (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Botulinum toxin type-A (BoNTA) has been considered a treatment option for CH. The aim of this study was to assess the effectiveness of BoNTA treatment in patients with medically resistant CH. Materials and Methods: Forty patients with CH were included in the study. Patients in the BoNTA group (n=20) were administered 10 U of BoNTA bilaterally to the frontal muscles, 20 U to the temporal muscles, 15 U to the semispinalis capitis, 15 U to the splenius capitis, and 15 U to the trapezius muscles (total: 150 U). Patients in the placebo group (n=20) received 0.2 mL of saline administrated to the same sites. All participations were evaluated 6 and 12 weeks after treatment; side effects, the number of painful days, severity (by visual analogue scale, VAS) and frequency of pain were evaluated. Results: In the BoNTA group, the severity and frequency of pain 6 and 12 weeks post treatment were significantly lower than pre-treatment levels (p

🔖

Cite This Article

ODABAŞI, Z., ÖZTÜRK, B., KÜTÜKÇÜ, Y., ULAŞ, Ü. H., KARADAŞ, Ö. (2022). The efficacy of botulinum toxin in patients with cervicogenic headache: A placebo-controlled clinical trial. Balkan Medical Journal, Cilt: 29 - Sayı: 2, 184–187. https://ajindex.com/articles/461691

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Sjaastad O, Saunte C, Hovdahl H, Breivik H, Grønbaek E. “Cervicogenic” headache. An hypothesis. Cephalalgia 1983;3:249-56. [CrossRef] 2. Fredriksen TA, Hovdal H, Sjaastad O. “Cervicogenic headache”: clinical manifestation. Cephalalgia 1987;7:147-60. [CrossRef] 3. IHS, Headache Classification Committee of the International Headache Society. The international Classification of headache disorders:2nd edition. Cephalalgia 2004;24:9-160. 4. Wight S, Osborne N, Breen AC. Incidence of ponticulus posterior of the atlas in migraine and cervicogenic headache. J Manipul Physiol Ther 1999;22:15-20. [CrossRef] 5. Hack G. Cervicogenic headache: new anatomical discovery provides the missing link. Chiroprac Rep 1998;12:1-3. 6. Mitchell BS, Humphreys BK, O’Sullivan E. Attachments of the ligamentum nuchae to cervical posterior spinal dura and the lateral part of the occipital bone. J Manipul Physiol Ther 1998;21:145-8. 7. Alix ME, Bates DK. A proposed etiology of cervicogenic headache: the neurophysiologic basis and anatomic relationship between the dura mater and the rectus posterior capitis minor muscle. J Manipul Physiol Ther 1999;22:534-9. [CrossRef] 8. Leone M, D’Amico D, Moschiano F, Farinotti M, Filippini G, Bussone G. Possible identification of cervicogenic headache among patients with migraine: an analysis of 374 headaches. Headache 1995;35:461-4. [CrossRef] 9. Rothbart P. Cervicogenic headache: a pain in the neck. Can J Diagnos 1996;13:64-6. 10. Sjaastad O, Fredriksen TA. Cervicogenic headache: criteria, classification and epidemiology. Clin Exp Rheumatol 2000;18:3-6. 11. Nilsson N. The prevalence of cervicogenic headache in a random population sample of 20-59 year olds. Spine 1995;20:1884-8. [CrossRef] 12. IHS, Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8:1-96. 13. Kränzlin P, Wälchli B. The concept of cervicogenic headache. Annual postgraduate course of the association of Swiss chiropractors, vol. 13. Interlaken, Switzerland: 1993. 14. Anthony M. Cervicogenic headache: prevalence and response to local steroid therapy. Clin Exp Rheumatol 2000;18:59-64. 15. Shah PA, Nafee A. Clinical profile of headache and cranial neuralgias. J Assoc Physicians India 1999;47:1072-5. 16. Bono G, Antonaci F, Ghirmai S, D’Angelo F, Berger M, Nappi G. Whiplash injuries: clinical picture and diagnostic work-up. Clin Exp Rheumatol 2000;18